A Randomised Phase II Study of Irinotecan in Combination with 5-FU/FA Compared with Irinotecan Alone as Second-Line Treatment of Patients with Metastatic Colorectal Carcinoma

2007 ◽  
Vol 30 (4) ◽  
pp. 169-174 ◽  
Author(s):  
Ullrich Graeven ◽  
Dirk Arnold ◽  
Anke Reinacher-Schick ◽  
Theodor Heuer ◽  
Arnd Nusch ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Metastatic Colorectal Carcinoma

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

2019 ◽  
Vol 63 (4) ◽  
Author(s):  
Salvatore Grisanti ◽  
Vittorio D. Ferrari ◽  
Michela Buglione ◽  
Giorgio M. Agazzi ◽  
Roberto Liserre ◽  
...  
Keyword(s):  
Systematic Review ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Glioblastoma ◽  
Line Treatment ◽  
Second Line ◽  
Review Of Literature

Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group

2011 ◽  
Vol 102 (6) ◽  
pp. 1171-1175 ◽  
Author(s):  
Hiroshi Kitamura ◽  
Keisuke Taguchi ◽  
Yasuharu Kunishima ◽  
Masahiro Yanase ◽  
Atsushi Takahashi ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Metastatic Urothelial Carcinoma

scholarly journals A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma

1999 ◽  
Vol 10 (8) ◽  
pp. 981-983 ◽  
Author(s):  
K.J. O'Byrne ◽  
P.A. Philip ◽  
D.J. Propper ◽  
I.P. Braybrooke ◽  
M.P. Saunders ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Folinic Acid ◽  
Phase Ii ◽  
Phase Ii Study ◽  
High Dose ◽  
Metastatic Colorectal Carcinoma

A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin

1991 ◽  
Vol 9 (4) ◽  
Author(s):  
RobertP. Whitehead ◽  
ThomasR. Fleming ◽  
JohnS. Macdonald ◽  
FrederickR. Ahmann ◽  
HarinderS. Garewal ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Colorectal Carcinoma

Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2021 ◽  
pp. clincanres.1789.2021
Author(s):  
E. Gabriela Chiorean ◽  
Katherine A Guthrie ◽  
Philip A Philip ◽  
Elizabeth M. Swisher ◽  
Florencia Jalikis ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Parp Inhibitor ◽  
Metastatic Pancreatic Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Randomized Phase Ii

scholarly journals Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer

2018 ◽  
Vol 29 ◽  
pp. viii259
Author(s):  
J.S. Yoon ◽  
K.-H. Lee ◽  
G.J. Cheon ◽  
Y.-J. Bang ◽  
D.-Y. Oh
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Tract Cancer

Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer

2001 ◽  
Vol 19 (1) ◽  
pp. 119-126 ◽  
Author(s):  
Christos Kosmas ◽  
Nicolas B. Tsavaris ◽  
Nikolaos A. Malamos ◽  
Maria Vadiaka ◽  
Christos Koufos
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Grade 3

PURPOSE: The aim of the present phase II study was to evaluate the efficacy of the paclitaxel, ifosfamide, and cisplatin (PIC) combination in relapsed small-cell lung cancer (SCLC). PATIENTS AND METHODS: Eligible patients were those with SCLC who had progressed or relapsed after therapy with carboplatin and etoposide (with or without chest radiotherapy). The PIC regimen consisted of paclitaxel 175 mg/m2 on day 1, ifosfamide 5 g/m2 divided over days 1 and 2, and cisplatin 100 mg/m2 divided over days 1 and 2; PIC was given every 21 days with granulocyte colony-stimulating factor support. RESULTS: Thirty-three patients (30 men and three women) were entered onto the study (median age, 62 years [range, 55 to 70 years]; median performance status, 1 [range, 0 to 2]). Metastatic sites at study entry included the lymph nodes (n = 13 patients), bone (n = 9), liver (n = 5), brain (n = 6), lung nodules (n = 8), adrenal glands (n = 9), and other (n = 2) Responses included eight complete remissions and 16 partial remissions (overall response rate, 73% [24 of 33 patients]). Five patients had stable disease and two had progressive disease. Median time to progression and overall survival were 21 and 28 weeks, respectively. The 1-year survival rate was 12%, with two patients alive without evidence of disease at 76 and 104 weeks since PIC initiation. Grade 3 and 4 toxicities included neutropenia in 30 patients (24 [73%] developed grade 4 neutropenia [ < 5 days]) and febrile neutropenia in six patients (18%); grade 3 or 4 thrombocytopenia was seen in nine patients (27%) . No grade 3 neuropathy was observed; grade 1 or 2 CNS toxicity was seen in five patients, there was no renal toxicity, grade 2 myalgias were seen in nine patients, grade 2 diarrhea was seen in one patient, and grade 3 nausea or vomiting was seen in seven patients. There were no treatment-related deaths. CONCLUSION: In the present phase II study, the PIC combination seemed highly active and tolerable in patients with relapsed SCLC when it was administered as second-line treatment. Given the present experience, an evaluation of the PIC regimen as front-line treatment of SCLC is planned.

Sign in / Sign up

Export Citation Format

Share Document